CD79A and acute lymphoblastic leukemia: Mikhailova et al. [61] selected extra B-cell markers, based on the expression of these markers in a cohort of 519 BCP-ALL patients, and they concluded that CD22, CD24, and cytosolic CD79a could substitute CD19 as B-cell specific markers for the identification of BCPs and BCP-ALL.